Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Cytokinetics, Incorporated (NASDAQ:CYTK). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Cytokinetics stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

Cytokinetics Trading Down 1.9%

NASDAQ:CYTK opened at $61.62 on Wednesday. The stock has a 50 day moving average of $71.13 and a 200-day moving average of $73.27. The firm has a market capitalization of $7.67 billion, a PE ratio of -8.53 and a beta of 0.41. Cytokinetics, Incorporated has a 52 week low of $54.30 and a 52 week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.13. The company had revenue of $28.62 million during the quarter, compared to the consensus estimate of $17.59 million. During the same period last year, the business posted ($1.12) EPS. The company’s revenue for the quarter was down 57.1% on a year-over-year basis. As a group, analysts predict that Cytokinetics, Incorporated will post -5.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cytokinetics news, EVP Andrew Callos sold 14,000 shares of Cytokinetics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total transaction of $1,118,320.00. Following the completion of the transaction, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,677,373.40. This trade represents a 19.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B. Parshall sold 5,000 shares of Cytokinetics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the transaction, the director directly owned 10,784 shares of the company’s stock, valued at approximately $770,840.32. The trade was a 31.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 191,426 shares of company stock worth $13,601,885 over the last three months. 2.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

CYTK has been the topic of a number of recent research reports. UBS Group upgraded Cytokinetics from a “neutral” rating to a “buy” rating and raised their target price for the company from $69.00 to $115.00 in a research note on Monday, June 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a research report on Friday, September 11th. JPMorgan Chase & Co. boosted their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Needham & Company LLC upped their target price on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Royal Bank Of Canada upped their target price on shares of Cytokinetics from $112.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Eighteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $106.06.

Institutional Investors Weigh In On Cytokinetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its holdings in shares of Cytokinetics by 8.6% in the 3rd quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 213 shares in the last quarter. Strs Ohio boosted its stake in Cytokinetics by 2.4% in the 1st quarter. Strs Ohio now owns 12,600 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 300 shares in the last quarter. AlphaCentric Advisors LLC boosted its stake in Cytokinetics by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 305 shares in the last quarter. Abel Hall LLC grew its position in Cytokinetics by 10.5% in the first quarter. Abel Hall LLC now owns 4,050 shares of the biopharmaceutical company’s stock valued at $267,000 after acquiring an additional 384 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new stake in Cytokinetics in the second quarter valued at $36,000.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Additional analyses from the Phase 3 ACACIA-HCM study further characterized aficamten’s effects across exercise-performance measures and patient responder groups. The data also supported the drug’s dose-adjustment approach and safety profile, potentially strengthening Cytokinetics’ case for aficamten as a future treatment for non-obstructive HCM. Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
• Positive Sentiment: Several market commentaries highlighted the Phase 3 aficamten results and the possibility that the drug’s multi-domain benefits could improve Cytokinetics’ long-term commercial outlook. The company’s pipeline and potential heart-drug opportunity are driving the fresh investor interest, although regulatory and commercialization risks remain. Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten in NHCM
• Neutral Sentiment: Wall Street Zen upgraded Cytokinetics to a “Hold,” suggesting a more balanced view of the shares after the recent clinical updates rather than a clearly bullish or bearish shift. Wall Street Zen Upgrades Cytokinetics to Hold
• Neutral Sentiment: Chief Executive Officer Robert I. Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance and he retained 278,544 shares, it is a limited signal of insider sentiment, though it may add modest pressure to investor perception. SEC Form 4 Filing

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.